文献速递临床试验与 GCP基础与转化研究

TLR7激动剂vesatolimod在HIV控制者中停药后适度延迟病毒反弹

The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy.
PubMed 文献 · Sci Transl Med · 2021-01-01

这项随机双盲安慰剂对照1b期试验在ART治疗的HIV-1控制者中评估口服TLR7激动剂vesatolimod(17例)与安慰剂(8例)每两周一次共10剂的效果。vesatolimod诱导免疫细胞活化、降低完整前病毒DNA,并在中断ART后适度延长病毒反弹时间,该延迟由治疗结束时较低完整前病毒DNA预测。

要点

  • vesatolimod可诱导免疫细胞活化并降低ART期间完整前病毒DNA。
  • 中断ART后vesatolimod组病毒反弹时间适度延长,由较低完整前病毒DNA预测。
  • 需更大规模临床研究评估vesatolimod联合方案对HIV长期控制的疗效。

核心结论

  • vesatolimod在ART治疗的HIV-1控制者中诱导免疫活化、降低完整前病毒DNA,并适度延迟中断ART后的病毒反弹。

研究设计与样本

  • 随机、双盲、安慰剂对照1b期临床试验,参与者按2:1随机接受vesatolimod(n=17)或安慰剂(n=8),每两周一次共10剂,期间继续ART。

主要发现

  • vesatolimod与免疫细胞活化诱导相关。
  • vesatolimod与ART期间完整前病毒DNA下降相关。
  • 中断ART后vesatolimod组病毒反弹时间适度增加,该延迟由末次给药后13天时较低完整前病毒DNA预测。
  • 推断通路分析提示给药后树突状细胞与自然杀伤细胞交互增加及细胞毒性潜力增加。

临床怎么用

  • 当前结果支持在更大规模临床研究中评估以vesatolimod为基础的联合方案用于HIV长期控制。

局限性

  • 样本量小(vesatolimod 17例、安慰剂8例),需更大规模临床研究评估疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Toll-like receptor 7 (TLR7) agonists, in combination with other therapies, can induce sustained control of simian-human immunodeficiency virus (SHIV) or simian immunodeficiency virus (SIV) in nonhuman primates. Here, we report the results of a randomized, double-blind, placebo-controlled phase 1b clinical trial of an oral TLR7 agonist, vesatolimod, in HIV-1-infected controllers on antiretroviral therapy (ART). We randomized participants 2:1 to receive vesatolimod (n = 17) or placebo (n = 8) once every other week for a total of 10 doses while continuing on ART. ART was then interrupted, and the time to viral rebound was analyzed using the Kaplan-Meier method. Vesatolimod was associated with induction of immune cell activation, decreases in intact proviral DNA during ART, and a modest increase in time to rebound after ART was interrupted. The delayed viral rebound was predicted by the lower intact proviral DNA at the end of vesatolimod treatment (13 days after the final dose). Inferred pathway analysis suggested increased dendritic cell and natural killer cell cross-talk and an increase in cytotoxicity potential after vesatolimod dosing. Larger clinical studies will be necessary to assess the efficacy of vesatolimod-based combination therapies aimed at long-term control of HIV infection.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. SenGupta D, Brinson C, DeJesus E, et al. The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy. Sci Transl Med. 2021. PMID: 34162752. doi:10.1126/scitranslmed.abg3071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。